Derfor bør tæt monitorering af den glykæmiske kontrol, dosisjustering inden for det anbefalede doseringsområde samt ændringer i diabetesbehandlingen overvejes, når kationstoffer, som elimineres via renal tubulær udskillelse, administreres samtidigt.
Therefore, close monitoring of glycaemic control, dose adjustment within the recommended posology and changes in diabetic treatment should be considered when cationic agents that are eliminated by renal tubular secretion are co-administered.